was higher after the company said its technology might be capable of rendering human immune-system cells permanently resistant to HIV infection.
The company said after the close Wednesday that the resistance can be achieved by using what are called zinc finger DNA-binding protein nucleases, or ZFN's.
Sangamo's ZFNs are designed to permanently modify the DNA sequence encoding CCR5, a co-receptor that enables HIV to enter and infect immune-system cells.
Shares of Sangamo were gaining 40 cents, or 7.4%, to $5.78.
The company presented the data at a conference in San Francisco.